Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
| ▸ | NMT2 | O60551 | 2/20 | 0.43 |
| ▸ | NMT1 | P30419 | 2/20 | 0.43 |
| ▸ | KDM5A | P29375 | 2/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319961 | 1.00 | BCHE (0.49) | BCHEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4317981 | 0.96 | BCHE (0.50) | BCHEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4317976 | 0.96 | BCHE (0.50) | BCHEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4313021 | 0.90 | BCHE (0.49) | BCHEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4313026 | 0.90 | BCHE (0.49) | BCHEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL8895540 | 0.89 | ALDH1A1 (0.50) | BCHEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL22758119 | 0.82 | MEN1 (0.53) | MEN1KMT2ANMT2NMT1KDM5A | |
| SCHEMBL15623775 | 0.82 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2APLA2G2A | |
| SCHEMBL4313039 | 0.81 | ALDH1A1 (0.51) | BCHEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4313036 | 0.81 | ALDH1A1 (0.51) | BCHEALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| CN-1416346-A | Peotease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | CN | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| CN-1416346-A | Peotease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | CN | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | BCHE 1055/4885ALDH1A1 2646/4885MEN1 637/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | BCHE 1005/4885ALDH1A1 3139/4885MEN1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.